Arretxe Garcia, Iñaki

Universitat Autònoma de Barcelona. Facultat de Biociències

English

Diposit Digital de Documents de la UAB

INTRODUCTIONIñaki Arretxe GarciaBiochemistry bachelor degree  │  Faculty of Biosciences  │  Autonomous University of BarcelonaInflammatory bowel disease and colorectal cancer:the role of microbiota· Inflammatory bowel disease (IBD) is a chronic intermittent disorder characterized by intestinal inflammation. · IBD patients have a higher risk of developing colorectal cancer (CRC).· Intestinal microbiota is presumed to play a large role in IBD and CRC pathogenesis.· Intestinal microbiota could contribute IBD-related CRC. ObjectivesThe aim of this review is to describe the role of intestinal microbiota in IBD-related CRC and to present molecular mechanisms whereby microbiota could drive carcinogenesis. VARIATIONS IN INTESTINAL MICROBIOTA TUMORIGENESIS DRIVING DYSBIOSISFigure 1. Factors involved in IBD-related CRC progression.Figure 3. Increased/decreased bacterial species in IBD and their role in colitis and tumorigenesisFigure 2. On the left, most frequent variations in intestinal microbiota of IBD and CRC patients; on the right, shared microbial pattern between IBD and CRC.IBD & CRC share similar microbial patternsBacteroides FusobacteriumEscherichia‘Butyrate-producingbacteria· IBD patients have a protumoral microbial pattern that brings CRC susceptibility.· Microbiota seems to contribute IBD-derived CRC, but it may not play the main role.· ETBF and F. nucleatum seem to be more related to tumorigenesis initiation.· AIEC mainly promotes colitis exacerbation and has a slight effect in tumorigenesis.· Synergistic effect of microbiota, combined with other factors, could drive IBD-related CRC.CONCLUSIONS· Monitoring IBD patients microbiota could help us understand the role of microbiota in IBD-related CRC, especially in those patients who develop CRC.· Pathobionts could be potential prognosis markers and therapeutic targets in both IBD and CRC.FUTURE PERSPECTIVESReferences1. Svrcek M, et al. Clinicopathological and Molecular Specificities of Inflammatory Bowel Disease-Related Colorectal Neoplastic Lesions: The Role ofInflammation. J Crohn’s Colitis. 2018; 12(12):1486-198.2. Chia-Hui Yu L. Microbiota dysbiosis and barrier dysfunction in inflammatory bowel disease and colorectal cancers: exploring a common groundhypothesis. J Biomed Sci. 2018;25(1):79.3. Chung L, et al. ETBF Coordinates a Pro-carcinogenic Inflammatory Cascade via Targeting of Colonic Epithelial Cells. Cell Host Microbe.2018;23(3):421.4. Yang Y, et al. Fusobacterium nucleatum Increases Proliferation of Colorectal Cancer Cells and Tumor Development in Mice by Activating Toll-LikeReceptor 4 Signaling to Nuclear Factor−κB, and Up-regulating Expression of MicroRNA-21. Gastroenterology. 2017;152(4):851-866.Figure 4. ETBF induced mechanisms involved in colitis and tumorigenesis initiation Figure 5. F. nucleatum role in tumorigenesis. IκB: inhibitor of κB; IKK: IκB kinase. Adapted from Yang Y, et al. Figure 6. AIEC role in colitis chronification and its contribution to tumorigenesis initiationPROTUMORAL PATHOBIONTSFigures 1, 3-6 where created with BioRender.com

Inflammatory bowel disease and colorectal cancer : the role of microbiota

https://ddd.uab.cat/pub/tfg/2020/233818/PosterTFG_InakiArretxe.pdf

Inflammatory bowel disease and colorectal cancer : the role of microbiota

Abstract

Similar works

Full text

Available Versions

Diposit Digital de Documents de la UAB